Details of the Drug Reposition

General Information of This Drug (ID: DMYXT2U)

Drug Name
Secukinumab   DMYXT2U
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plaque psoriasis DISQX1LF EA90.0 Approved [1]
------------------------------------------------------------------------------------
7 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Type-1 diabetes DIS7HLUB 5A10 Phase 2 [2]
Multiple sclerosis DISB2WZI 8A40 Phase 2 [2]
Dry eye disease DISK72WC 9E1Z Phase 2 [2]
Atopic dermatitis DISTCP41 EA80 Phase 2 [2]
Alopecia DIS37HU4 ED70 Phase 2 [2]
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [2]
Psoriatic arthritis DISLWTG2 FA21 Phase 2 [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate